pH-responsive targeted nanoparticles release ERK-inhibitor in the hypoxic zone and sensitize free gemcitabine in mutant K-Ras-addicted pancreatic cancer cells and mouse model.

Therapeutic options for managing Pancreatic ductal adenocarcinoma (PDAC), one of the deadliest types of aggressive malignancies, are limited and disappointing. Therefore, despite suboptimal clinical effects, gemcitabine (GEM) remains the first-line chemotherapeutic drug in the clinic for PDAC treatm...

Full description

Bibliographic Details

Published in:	PLoS ONE
Main Authors:	Debasmita Dutta, Priyanka Ray, Archana De, Arnab Ghosh, Raj Shankar Hazra, Pratyusha Ghosh, Snigdha Banerjee, Francisco J Diaz, Sunil P Upadhyay, Mohiuddin Quadir, Sushanta K Banerjee
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2024-01-01
Online Access:	https://doi.org/10.1371/journal.pone.0297749